Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
SAN DIEGO , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
View HTML
Toggle Summary Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
SAN DIEGO , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), the patient and
View HTML
Toggle Summary Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy (IgAN), a rare kidney disorder often resulting in end-stage renal disease, during the 15 th
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October: Cantor Global Healthcare Conference Date: Monday, October 1, 2018 Time: 4:40 p.m.
View HTML
Toggle Summary Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering
SAN DIEGO , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) to be sold in an underwritten offering.
View HTML
Toggle Summary Retrophin Announces Proposed Convertible Senior Notes Offering
SAN DIEGO , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in an underwritten offering.
View HTML
Toggle Summary Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg , M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20 years of
View HTML
Toggle Summary Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan
Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; top-line results expected in early 2019 Retrophin Chief Executive Officer Stephen Aselage
View HTML
Toggle Summary Retrophin to Report Second Quarter 2018 Financial Results
SAN DIEGO , July 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent
SAN DIEGO , June 14, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent covering the Company’s product candidate sparsentan which, in addition to being in Phase 3 clinical development for the
View HTML